MyFinsight
Home
Blog
About
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$14,576K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Non-cash lease expense
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
Operating lease liabilities
Purchases of marketable securiti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-14,964
-6,631
-7,144
-19,601
Depreciation and amortization
374
255
290
746
Stock-based compensation expense
1,097
1,041
407
1,334
Accretion of discount on marketable securities
122
161
130
379
Gain on sale of fixed assets
-
288
-
-
Gain on sale of property and equipment
116
-
0
288
Asset impairment
808
0
-
-
Non-cash lease expense
1,347
651
636
1,239
Prepaid expenses and other assets
160
-398
86
236
Accounts payable and accrued expenses
-1,203
-197
-1,882
-3,351
Operating lease liabilities
-1,334
-631
-594
-1,026
Deferred revenue
-2
-1,880
-1,229
-1,533
Other long-term liabilities
0
-1
0
133
Net cash used in operating activities
-14,563
-7,156
-9,732
-22,962
Purchases of property and equipment
13
0
72
-
Proceeds from sales of property and equipment
717
0
0
963
Purchases of marketable securities
1,230
11,840
1,719
15,457
Maturities of marketable securities
16,221
12,914
19,675
39,838
Net cash provided by investing activities
15,695
1,074
17,884
25,344
Proceeds from issuance of common stock
25
5
0
14
Net cash provided by financing activities
25
5
0
14
Net increase (decrease) in cash
1,157
-6,077
8,152
2,396
Cash, cash equivalents and restricted cash at beginning of year
13,441
19,518
8,970
-
Cash, cash equivalents and restricted cash at end of period
14,598
13,441
19,518
-
Cash and cash equivalents
12,860
-
-
-
Restricted cash
1,738
-
-
-
Total cash, cash equivalents and restricted cash
14,598
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$16,221K
(-59.28%↓ Y/Y)
Proceeds from issuance of
common stock
$25K
(78.57%↑ Y/Y)
Proceeds from sales of
property and equipment
$717K
(-25.55%↓ Y/Y)
Net cash provided by
investing activities
$15,695K
(-38.07%↓ Y/Y)
Net cash provided by
financing activities
$25K
(78.57%↑ Y/Y)
Canceled cashflow
$1,243K
Net increase
(decrease) in cash
$1,157K
(-51.71%↓ Y/Y)
Canceled cashflow
$14,563K
Purchases of marketable
securities
$1,230K
(-92.04%↓ Y/Y)
Purchases of property and
equipment
$13K
Non-cash lease expense
$1,347K
(8.72%↑ Y/Y)
Stock-based compensation
expense
$1,097K
(-17.77%↓ Y/Y)
Asset impairment
$808K
Depreciation and
amortization
$374K
(-49.87%↓ Y/Y)
Net cash used in
operating activities
-$14,563K
(36.58%↑ Y/Y)
Canceled cashflow
$3,626K
Net loss
-$14,964K
(23.66%↑ Y/Y)
Operating lease
liabilities
-$1,334K
(-30.02%↓ Y/Y)
Accounts payable and
accrued expenses
-$1,203K
(64.10%↑ Y/Y)
Prepaid expenses and
other assets
$160K
(-32.20%↓ Y/Y)
Accretion of discount on
marketable securities
$122K
(-67.81%↓ Y/Y)
Gain on sale of
property and equipment
$116K
(-59.72%↓ Y/Y)
Deferred revenue
-$2K
(99.87%↑ Y/Y)
Buy us a coffee